News for Agenus Inc. (AJ81.F)

LEXINGTON, Mass., Feb. 09, 2021 -- Agenus Inc. , an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate... | February 9, 2021

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of checkpoint ...

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. AGEN, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell

6 total confirmed objective clinical responses in colon, ovarian, and endometrial cancersNo complement-mediated toxicities reported LEXINGTON, Mass., Feb. 09, 2021 -- Agenus Inc. , an... | February 9, 2021

Agenus Inc (NASDAQ: AGEN) has announced positive preliminary results from its Phase 1 trial evaluating its iNKT cell therapy ...